Jordan Mackay Graff MD FACS
Retinal Disease
Parter, BDP Eye Center Clinical Assist. Professor Ophthalmology UA Phx
Join to View Full Profile
4800 N 22nd StSte 120Phoenix, AZ 85016
Phone+1 602-955-1000
Fax+1 602-508-4830
Dr. Graff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Iowa Hospitals and ClinicsFellowship, Surgical Retina and Vitreous, 2007 - 2009- University of Iowa Hospitals and ClinicsResidency, Ophthalmology, 2004 - 2007
- University of Iowa Hospitals and ClinicsInternship, Internal Medicine, 2003 - 2004
University of California, Irvine, School of MedicineClass of 2003
Certifications & Licensure
AZ State Medical License 2009 - 2025
IA State Medical License 2003 - 2011
American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
- Fellow (FAAO) American Academy of Ophthalmology
Publications & Presentations
PubMed
- 2 citationsRetinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study.Aamir A Aziz, Arshad M Khanani, Hannah Khan, Eileen Lauer, Ibrahim Khanani
Eye. 2025-04-01 - Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial.Arshad M Khanani, Peter A Campochiaro, Jordan M Graff, Dennis M Marcus, Daniel Miller
JAMA Ophthalmology. 2025-04-01 - 1 citationsInterim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration.Peter A Campochiaro, David Eichenbaum, Margaret A Chang, W Lloyd Clark, Jordan M Graff
Ophthalmology. Retina. 2025-02-01
Press Mentions
FDA Approves Susvimo for Diabetic Macular EdemaFebruary 6th, 2025- FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related BlindnessFebruary 4th, 2025
- Mehrdad Ghoreishi, MD, a Cardiothoracic Surgeon with University of Maryland Medical CenterJune 15th, 2022
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
